Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study
about
Benralizumab: a unique IL-5 inhibitor for severe asthmaEosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary diseaseTargeted anti-inflammatory therapeutics in asthma and chronic obstructive lung diseasePositioning new pharmacotherapies for COPDNovel Therapies for Eosinophilic DisordersAnti-IL5 therapy for asthma and beyondInterleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needsTherapeutic Potential of Medicinal Plants and Their Constituents on Lung Inflammatory DisordersPharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewPersonalized Medicine in AllergyAdvances in understanding COPDCorrelation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD.Biologic therapies targeting eosinophils: current status and future prospects.A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Does eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit?Treatment with intranasal iloprost reduces disease manifestations in a murine model of previously established COPDCurrent concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.A review on airway biomarkers: exposure, effect and susceptibility.Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.What goes up must come down: biomarkers and novel biologicals in severe asthma.An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease.Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.Update in Chronic Obstructive Pulmonary Disease 2014.The use of cellular and molecular biomarkers to manage COPD exacerbations.Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators.Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity.The Reemergence of the Asthma-COPD Overlap Syndrome: Characterizing a Syndrome in the Precision Medicine Era.Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.The clinical profile of benralizumab in the management of severe eosinophilic asthma.Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).The path to personalized medicine in asthma.Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Nothing New Under the Sun.Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease.Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study.Management of the Asthma-COPD Overlap Syndrome (ACOS): a Review of the Evidence.Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations.A Mathematical Modeling Approach to Understanding the Effect of Anti-Interleukin Therapy on Eosinophils.Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD.Human group 2 innate lymphoid cells do not express the IL-5 receptor.Myeloid-derived suppressor cell-like fibrocytes are increased and associated with preserved lung function in chronic obstructive pulmonary disease.
P2860
Q26750711-3B54A19C-41E9-4BB7-97AE-EC25ADDAAA04Q26771819-728B3B8E-1DCF-4671-B178-83B6D7313567Q26786229-E05238D1-5118-4AAE-8742-564AE7FAE1ECQ26798659-97D93138-1926-4DCE-BF1C-B1010DCD1B34Q26799600-C5437712-D416-4D15-ACB9-168BBB4C58CAQ26866943-27B84CE7-4443-4118-AC5C-58DB4187AD32Q28067081-DCF965AB-2DD0-45D3-8687-795811ED0142Q28067576-B3F7D948-6AC2-449D-9E36-59BA74CC5459Q28070274-4D4C90E6-1314-445A-9E38-D0FFA1DD2F56Q28073074-1B54410E-0621-4615-8201-1A88364DCEFBQ28074701-EB3A4E80-39BD-41B2-8B4F-EEDD740A8712Q33627868-A3276739-39A9-4627-8659-1B0EDCB83803Q35565533-770AD8B1-C5A7-4E1E-8B81-24766E3AF529Q35838507-6BB7B1CF-F38E-4CC2-8E79-13259FFE15BCQ36067407-53D2ACF0-F4CB-49F3-9DA1-EA73964CB44AQ36775760-99690E74-2D68-4598-959E-EA1585144BE9Q36907742-F57E47CD-2EC0-4AF8-8C5B-860FF8B03477Q38308369-E02C65B6-53E4-4DAD-BA42-EC4AD609155DQ38314318-73399558-D6B2-4402-B418-3AB227D472CFQ38339755-7A7FA1BB-3331-4403-B721-86AE88921423Q38399184-2F1A5062-C2D8-4CF4-BF5D-344762B610D3Q38434820-57FD27C5-DDE2-42CD-8F65-D666FD28DA90Q38620368-7E7C8D54-8F8C-485D-B1B4-457F5E089E98Q38739067-AF8DE4DD-D5FF-4E41-8FF9-D7AC48216436Q38751226-1323BE94-852B-4445-95DB-E806926A8C53Q38779718-1B85365C-41C3-4F21-8094-178525588E70Q38802244-F66378B6-DA8B-426F-98C0-71F0962C85F0Q38818964-9DC0E8A6-B76E-4777-BB75-88B1C9603DF0Q38822826-894043A8-E8B2-46D3-BB26-7AF23D25A934Q38837317-E30DA425-FD1F-4321-9AC6-8A301E4CC8AEQ38843261-D2BA3D94-87B0-4415-BEB4-C7347308E269Q38892965-E1CB2BA7-4998-4F62-A38D-15AC1A04765CQ38923185-3F9CA27D-1E1E-4364-90DB-F674E7244718Q38934768-8A5CBCE7-53C5-468F-A0A1-00791F2ED9A0Q39173650-02EA5F8D-8091-4934-94D5-6D434A3391B0Q39189229-BDCA2D24-8DB3-44C7-91AA-C121949FC2B3Q40067123-CFCCC5F7-E3D3-49E1-B0AA-E5C38602AE9DQ40176175-17F866B4-CD1D-4A82-8D53-14942FF1D3C6Q40213557-C349AF6B-17EC-4AF3-9F7D-25E1240BCB82Q40515227-CFF36732-AE92-40E6-A68B-D067646AB067
P2860
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 September 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Benralizumab for chronic obstr ...... ebo-controlled, phase 2a study
@en
Benralizumab for chronic obstr ...... bo-controlled, phase 2a study.
@nl
type
label
Benralizumab for chronic obstr ...... ebo-controlled, phase 2a study
@en
Benralizumab for chronic obstr ...... bo-controlled, phase 2a study.
@nl
prefLabel
Benralizumab for chronic obstr ...... ebo-controlled, phase 2a study
@en
Benralizumab for chronic obstr ...... bo-controlled, phase 2a study.
@nl
P2093
P2860
P921
P1476
Benralizumab for chronic obstr ...... ebo-controlled, phase 2a study
@en
P2093
Christine K Ward
Claire Birrell
Eugene R Bleecker
René van der Merwe
Reynold A Panettieri
P2860
P304
P356
10.1016/S2213-2600(14)70187-0
P577
2014-09-07T00:00:00Z